EMA Authorised: Skytrofa (previously Lonapegsomatropin Ascendis Pharma) (Lonapegsomatropin) — Ascendis Pharma Endocrinology Division A/S

View source ↗

Summary

The European Medicines Agency authorised Skytrofa (lonapegsomatropin) from Ascendis Pharma Endocrinology Division A/S for growth hormone deficiency, with orphan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Skytrofa (lonapegsomatropin)

Snippet

Status: Authorised. Therapeutic area: Growth and Development. MAH: Ascendis Pharma Endocrinology Division A/S. Decision date: 22/05/2025. Orphan medicine